New drug combo shows promise in ovarian cancer fight

NCT ID NCT05446870

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 10, 2026 · Updated 22 times

Summary

This study tested whether adding an experimental drug (MK-4830) to standard chemotherapy and immunotherapy (pembrolizumab) could better reduce tumor DNA in the blood of people with advanced ovarian cancer. 160 participants with stage III or IV high-grade serous ovarian cancer were enrolled. The goal was to see if the combination improved treatment response before surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AZ Maria Middelares-IKG ( Site 1302)

Ghent, Oost-Vlaanderen, 9000, Belgium
Antwerp University Hospital-Oncology ( Site 1301)

Edegem, Antwerpen, 2650, Belgium
Centre Hospitalier de l'Université de Montréal ( Site 0300)

Montreal, Quebec, H2X 3E4, Canada
Changhua Christian Hospital-Obstetrics and Gynecology ( Site 1203)

Changhua County, Changhua, 50006, Taiwan
FALP ( Site 0905)

Santiago, Region M. de Santiago, 7500921, Chile
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 050

Milan, Lombardy, 20133, Italy
Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 0502)

Rome, Lazio, oo168, Italy
Fred Hutchinson Cancer Center ( Site 0100)

Seattle, Washington, 98109, United States
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101)

Barcelona, 08035, Spain
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104)

Madrid, Madrid, Comunidad de, 28041, Spain
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1103)

Hospitalet, Barcelona, 08907, Spain
Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 0501)

Milan, 20141, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 0

Naples, Campania, 80131, Italy
James Lind Centro de Investigación del Cáncer ( Site 0903)

Temuco, Araucania, 4800827, Chile
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0107)

New York, New York, 10016, United States
Mackay Memorial Hospital ( Site 1204)

Taipei, 10449, Taiwan
Mayo Clinic in Florida ( Site 0101)

Jacksonville, Florida, 32224, United States
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 0701)

Siedlce, Masovian Voivodeship, 08-110, Poland
McGill University Health Centre ( Site 0301)

Montreal, Quebec, H4A 3J1, Canada
Memorial Sloan Kettering Cancer Center ( Site 0102)

New York, New York, 10065, United States
Miami Cancer Institute at Baptist Health, Inc. ( Site 0110)

Miami, Florida, 33176, United States
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit

Warsaw, Masovian Voivodeship, 02-781, Poland
National Cancer Centre Singapore ( Site 1501)

Singapore, Central Singapore, 168583, Singapore
National Cheng Kung University Hospital ( Site 1201)

Tainan, 704, Taiwan
National Taiwan University Hospital-Internal Medicine ( Site 1200)

Taipei, 10002, Taiwan
National University Hospital ( Site 1502)

Singapore, South West, 119074, Singapore
Northwestern Memorial Hospital ( Site 0104)

Chicago, Illinois, 60611, United States
ONCOCENTRO APYS-ACEREY ( Site 0904)

Viña del Mar, Valparaiso, 2520598, Chile
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0116)

Mineola, New York, 11501, United States
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0900)

Santiago, Region M. de Santiago, 8330032, Chile
Rambam Health Care Campus-Gyneco-oncology unit ( Site 0602)

Haifa, 3109601, Israel
Roswell Park Cancer Institute ( Site 0106)

Buffalo, New York, 14263, United States
Rutgers Cancer Institute of New Jersey ( Site 0114)

New Brunswick, New Jersey, 08901, United States
Sanford Cancer Center-Gynecologic Oncology ( Site 0115)

Sioux Falls, South Dakota, 57104, United States
Seoul National University Hospital ( Site 0801)

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 0800)

Seoul, 03722, South Korea
Shaare Zedek Medical Center ( Site 0601)

Jerusalem, 9103102, Israel
Sheba Medical Center-ONCOLOGY ( Site 0600)

Ramat Gan, 5265601, Israel
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 0708)

Kielce, Świętokrzyskie Voivodeship, 25-734, Poland
Taichung Veterans General Hospital-GYNECOLOGY ( Site 1202)

Taichung, 407, Taiwan
UZ Leuven ( Site 1300)

Leuven, Vlaams-Brabant, 3000, Belgium
University of Colorado Anschutz Medical Campus-Cancer Clinical Trials Office ( Site 0108)

Aurora, Colorado, 80045, United States
Uniwersytecki Szpital Kliniczny w Poznaniu-Oddzial Ginekologii Onkologicznej ( Site 0709)

Poznan, Greater Poland Voivodeship, 61-848, Poland
Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi

Gdansk, Pomeranian Voivodeship, 80-214, Poland
Washington University ( Site 0113)

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

HIGH-GRADE SEROUS OVARIAN CARCINOMA OVARIAN CARCINOMA